ICNMD 2027

  • #ICNMD2027
SUBSCRIBE TO MAILING LIST
Facebook-f X-twitter Linkedin

Registration

Registration 2027

More details to come soon.

Registration is Now Closed
Thank You for Attending ICNMD 2026

Registration for ICNMD 2026 is now closed. Thank you to everyone who joined us in Florence, Italy, for the 19th International Congress on Neuromuscular Diseases. We appreciate your participation and support in making this congress a memorable success. We look forward to welcoming you to ICNMD 2027 in Chiba, Japan, 5-9 July 2027

REGISTER NOW
Early Registration (Until 27 March 2026)Regular Registration (Until 29 May 2026)Late/Onsite Registration (After 29 May 2026)
Full Registration€775 €875€975
Full Registration (Student, Trainee, Resident)*€575€675€775
Full Registration (Low Middle-Income Country)€575€675€775
Single Day Registration€325€425€525

*Proof of Student, Trainee or Resident status is required at time of registration. Please provide an official letter on your Institution’s letterhead indicating your status. It can be uploaded on the “Registration Options” page.  

Registration fees are inclusive of tax.

According to the EFPIA Code of Practice – 2025 Edition, in line with EU legislation (Directive 2001/83/EC), certain parts of medical conferences that contain promotional content, such as exhibition halls, must be accessible only to qualified healthcare professionals (HCPs). Access for non-HCPs (e.g., patients, general public) is explicitly restricted to maintain compliance.

Full Registration Includes:
  • Access to all Scientific Sessions (Except ticketed sessions)  
  • Access to Exhibit Hall & Posters   
  • Welcome Reception 
  • Networking Breaks and Lunch 
  • Industry Sponsored Symposia 
Single Day Registration Includes:
  • Access to all Scientific Sessions on the day(s) purchased (Except ticketed sessions)  
  • Access to Exhibit Hall & Posters  
  • Networking Breaks and Lunch on the day(s) purchased 
  • Industry Sponsored Symposia on the day(s) purchased 
Terms and Conditions

Registration and attendance at, or participation in ICNMD 2026 constitute an agreement by the registrant to the organizer’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes.

By allowing an exhibitor/sponsor to scan your badge, you will be consenting to your contact information being shared with that exhibitor/sponsor (name, job title, organization, city, country & email). Should you not wish to share your personal information with an exhibitor/sponsor, there is no obligation to allow your badge to be scanned by these parties. 

For online registration, we only accept credit card payments with American Express, Visa or Mastercard.  For onsite registration, we only accept American Express, Visa or Mastercard. Full payment is due prior to obtaining your badge for entry to the Congress. Cash and Cheques will NOT be accepted. 

Payment must be received by each registration deadline to qualify for the deemed rate. If not received, your registration will be automatically changed to the next tier rate, and a secondary invoice will be sent to you for the difference.

As per guidance and restrictions by the Italian Medicines Agency (AIFA), Patients and Representatives of Patient Organisations are not permitted to attend ICNMD.
 
The Italian Medicines Agency (AIFA) refers to Legislative Decree 219/06, particularly Articles 115 and 119 (official text in Italian at: https://gazzettaufficiale.it/eli/id/2006/06/21/006G0237/sg)
 
English Translation:
 
Article 115 – Restrictions on Public Advertising
Medicines may be advertised to the public only if, due to their composition and therapeutic purpose, they are intended for use without the intervention of a physician for diagnosis, prescription, or treatment monitoring, and, if necessary, with the advice of a pharmacist.
 
Public advertising of medicines that require a prescription or contain psychotropic or narcotic substances is prohibited; however, the Ministry of Health may authorize vaccination campaigns promoted by pharmaceutical companies.
 
The distribution of medicines to the public for promotional purposes is prohibited.
 
Except as provided in paragraph 2, public advertising of medicines partially or fully covered by the National Health Service is prohibited, as well as advertising of the medicines referred to in Articles 3 and 5.
In print publications, radio or television broadcasts, or other messages not of an advertising nature, it is prohibited to depict a medicine or its name in a context that may encourage its consumption.
 
Article 119 – Advertising to Healthcare Professionals
Advertising of a medicine may be directed only to healthcare professionals authorized to prescribe or dispense it.
 
Scientific information directed to healthcare professionals must comply with the criteria and guidelines adopted by AIFA, following consultation with the Permanent Conference for Relations between the State, the Regions, and the Autonomous Provinces, and after hearing the pharmaceutical industry associations.
 
Advertising to healthcare professionals must always include the summary of product characteristics as authorized, specify the medicine’s classification for supply purposes, and indicate the sale price and conditions for any dispensing at the expense of the National Health Service.
 
By way of exception, advertising may be limited to the medicine name and the generic name of the active substance(s), and may include the MAH (Marketing Authorization Holder) and the entity responsible for marketing the product.
 
Implementation of advertising may be carried out by another pharmaceutical company under a specific agreement with the MAH, without relieving the MAH of its obligations.
 
If promotional information violates AIFA provisions, the Agency may:
a) order immediate cessation or suspension of the promotion;
b) require the dissemination of a corrective notice at the violator’s expense.
 
These provisions apply without prejudice to regional regulations.
 
Note on Article 119:
Article 48, paragraph 21, of Decree-Law No. 269/2003 states that regions regulate:
  • advertising to doctors, healthcare professionals, and pharmacists;
  • provision of free samples;
  • granting of promotional items of negligible value;
  • reporting methods for National Health Service personnel participation in initiatives promoted or funded by pharmaceutical companies or medical device suppliers.

Discounted registration fees are available for Low-Middle Income Countries based on the World Bank classifications, click here for the associated list of countries.  

The registration system does support registering a group of attendees with one payment transaction.  If you would like to register more than one attendee at once, please contact icnmd-registration@icsevents.com for more information. 

Registration cancellations received in writing at the ICNMD 2026 Secretariat’s address by 29 May 2026, will be accepted and all fees refunded, less a EUR 100.00 administrative fee, as per Committee policy. Cancellations received after 29 May 2026, will not be refunded; however, transfer of your registration to another person is permitted by re-accessing the original delegate’s registration via the confirmation letter and replacing with the new delegate. No refunds will be made for non-attendance at the Congress.  

In the unlikely event that the Congress is cancelled, travel and accommodation costs will not be refunded.

An official letter of invitation to obtain a travel visa and authorization to attend the 19th International Congress on Neuromuscular Diseases will be issued ONLY after registration has been completed and full payment received by the Registration Team (ICNMD 2026 Congress Secretariat). 

It is the delegate’s responsibility to determine his/her requirements for entry into Italy.  

For more information on Italy entry requirements, please click here.

Contact Us

If you have any questions regarding registration for ICNMD 2026, do not hesitate to contact us at icnmd-registration@icsevents.com. 

Print PDF